See more : Fox Factory Holding Corp. (FOXF) Income Statement Analysis – Financial Results
Complete financial analysis of Innovent Biologics, Inc. (IVBXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innovent Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sino Wealth Electronic Ltd. (300327.SZ) Income Statement Analysis – Financial Results
- Handelsinvest Europa (HAIEU.CO) Income Statement Analysis – Financial Results
- BEAUTY GARAGE Inc. (3180.T) Income Statement Analysis – Financial Results
- TEB Bancorp, Inc (TBBA) Income Statement Analysis – Financial Results
- LG H&H Co., Ltd. (051900.KS) Income Statement Analysis – Financial Results
Innovent Biologics, Inc. (IVBXF)
About Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.21B | 4.56B | 4.27B | 3.84B | 1.05B | 9.48M | 18.54M | 32.13M |
| Cost of Revenue | 1.81B | 930.99M | 573.04M | 387.76M | 124.88M | -1.31M | -71.47M | 0.00 |
| Gross Profit | 4.40B | 3.63B | 3.70B | 3.46B | 922.65M | 10.79M | 90.01M | 32.13M |
| Gross Profit Ratio | 70.89% | 79.57% | 86.58% | 89.91% | 88.08% | 113.84% | 485.54% | 100.00% |
| Research & Development | 2.23B | 2.87B | 2.48B | 1.85B | 1.29B | 1.22B | 611.92M | 384.65M |
| General & Administrative | 750.28M | 835.49M | 884.03M | 436.87M | 255.30M | 277.50M | 87.77M | 57.38M |
| Selling & Marketing | 3.10B | 2.59B | 2.73B | 1.34B | 1.19B | 136.01M | 9.94M | 5.03M |
| SG&A | 3.85B | 3.43B | 3.61B | 1.78B | 1.45B | 413.51M | 87.77M | 57.38M |
| Other Expenses | 0.00 | -90.20M | -45.13M | -130.69M | -41.38M | -4.34B | -51.01M | -123.20M |
| Operating Expenses | 5.07B | 6.21B | 6.05B | 3.50B | 2.70B | 1.56B | 643.27M | 413.27M |
| Cost & Expenses | 7.89B | 7.14B | 6.62B | 3.89B | 2.83B | 1.56B | 643.27M | 413.27M |
| Interest Income | 452.84M | 189.54M | 151.76M | 116.10M | 102.70M | 20.68M | 7.98M | 4.54M |
| Interest Expense | 98.62M | 101.70M | 62.46M | 68.35M | 59.49M | 68.97M | 57.23M | 53.80M |
| Depreciation & Amortization | 385.10M | 319.42M | 204.75M | 85.63M | 86.37M | 64.06M | 61.10M | 53.35M |
| EBITDA | -660.68M | -1.75B | -2.37B | -704.74M | -1.57B | -5.74B | -597.72M | -359.92M |
| EBITDA Ratio | -10.65% | -38.51% | -68.11% | -19.11% | -150.52% | -60,586.43% | -3,430.40% | -1,413.33% |
| Operating Income | -1.68B | -2.07B | -3.11B | -820.14M | -1.66B | -1.79B | -750.14M | -461.54M |
| Operating Income Ratio | -27.06% | -45.52% | -72.91% | -21.34% | -158.76% | -18,841.75% | -4,046.48% | -1,436.60% |
| Total Other Income/Expenses | 534.89M | -96.54M | 61.63M | -301.53M | -56.86M | -4.32B | -91.32M | -131.19M |
| Income Before Tax | -1.14B | -2.17B | -3.05B | -858.71M | -1.72B | -5.87B | -716.05M | -544.46M |
| Income Before Tax Ratio | -18.44% | -47.64% | -71.46% | -22.34% | -164.19% | -61,970.90% | -3,862.61% | -1,694.69% |
| Income Tax Expense | -116.50M | 8.80M | 87.04M | 139.71M | 56.86M | 27.48M | -244.37M | -150.97M |
| Net Income | -1.03B | -2.18B | -3.14B | -998.42M | -1.78B | -5.77B | -562.32M | -504.20M |
| Net Income Ratio | -16.56% | -47.83% | -73.50% | -25.97% | -169.62% | -60,899.99% | -3,033.33% | -1,569.40% |
| EPS | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| EPS Diluted | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| Weighted Avg Shares Out | 1.56B | 1.49B | 1.45B | 1.35B | 1.18B | 334.68M | 1.12B | 1.12B |
| Weighted Avg Shares Out (Dil) | 1.56B | 1.49B | 1.46B | 1.36B | 1.18B | 334.68M | 1.12B | 1.12B |
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
AnHeart Therapeutics and Innovent Announce China's NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Innovent Announces Retirement of CFO and Appointment of New CFO
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
Source: https://incomestatements.info
Category: Stock Reports